Lead Product(s): BIO-205
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: MPM Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2020
The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.